Clinical trial NCT00788684: Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
Official title: A Phase 1 Study Evaluating the Safety of ABT-263 in Combination With Rituximab in Subjects With CD20-positive Lymphoid Malignancies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: CD20-Positive Lymphoid Malignancies
Chronic Lymphoid Leukemia
Hematological Malignancies
Non-Hodgkin's Lymphoma
Keywords: Non-Hodgkin's Lymphoma
Rituximab
Chronic Lymphoid Leukemia
Hematological Malignancies
ABT-263
Navitoclax
CD20-Positive Lymphoid Malignancies
Lead sponsor: AbbVie
Sponsor class: INDUSTRY
Collaborators: name: Genentech, Inc.
First posted: 2008-11-11
Enrollment: 29
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a Phase 1 study evaluating the safety of ABT-263 administered in combination with rituximab in participants with CD20-positive lymphoproliferative disorders. The extension portion of the study will allow active participants to continue to receive ABT-263 for up to 14 years after the last participant transitions with quarterly study evaluations.


Eligibility criteria: Inclusion Criteria:

* Diagnosed with a CD20-positive lymphoproliferative disorder (Revised European American Lymphoma \[REAL\]/World Health Organization \[WHO\]) and bi-dimensionally measurable disease with at least 1 lesion \>= 1.0 cm
* Eastern Cooperative Oncology Group (ECOG) performance score of \<= 1
* Adequate bone marrow function, independent of growth factor support (with the exception of participants with bone marrow that is heavily infiltrated with underlying disease \[80% or more\] who may use growth factor to achieve Absolute Neutrophil count (ANC) eligibility criteria) per local laboratory reference range as follows: Absolute Neutrophil count (ANC) \>= 1000/μL; Platelets \>= 100,000/mm3 (untransfused); Hemoglobin \>= 9.0 g/dL.
* Participants who have a history of autologous stem cell transplant (e.g., bone marrow) must be \> 6 months post transplant and have adequate bone marrow function, independent of any growth stimulating factors (with the exception of participants with bone marrow that is heavily infiltrated with underlying disease \[80% or more\] who may use growth factor to achieve ANC eligibility criteria) per local laboratory reference range as follows: Absolute Neutrophil count (ANC) \>= 1500/μL; Platelets \>= 125,000/mm3 (untransfused); Hemoglobin \>= 10.0 g/dL.
* Participant must have adequate renal, hepatic and coagulation function per local laboratory reference range as follows: Serum creatinine \<= 2.0 mg/dL or calculated creatinine clearance \>= 50 mL/min; AST and ALT \<= 3.0 × the upper normal limit (ULN); Bilirubin \<= 1.5 × ULN. Participants with Gilbert's Syndrome may have a Bilirubin \> 1.5 × ULN; activated partial thromboplastin time (aPTT), prothrombin time (PT) not to exceed 1.2 × ULN
* Females must be surgically sterile, postmenopausal (at least 1 year), or have negative pregnancy test at screening on serum sample obtained within 14 days prior to initial study drug administration, and prior to dosing on a urine obtained on Lead-in Day 1, if it has been \> 7 days since obtaining the serum pregnancy test results. Females not surgically sterile or postmenopausal (at least 1 year) and non-vasectomized males must practice at least 1 of the following: total abstinence from sexual intercourse (minimum 1 complete menstrual cycle),a vasectomized partner, hormonal contraceptives for at least 3 months prior to study drug administration, or double-barrier method.

Inclusion Criteria (Extension Study) Participants who enter the Extension Study must continue to meet all Inclusion and Exclusion criteria, with the exception of inclusion criteria regarding measurable disease and inclusion criteria regarding laboratory parameters. Participants entering the Extension Study must also have stable lab values per local laboratory reference ranges. In addition they must meet the following lab criteria:

* Participants must meet the following hematology and coagulation lab criteria:

  * Platelet counts must be \>= 25,000/mm3 (untransfused). Platelet counts \<= 50,000/mm3 must be stable and monitored at an increased frequency at the discretion of the investigator.
  * Absolute Neutrophil count (ANC) \>= 500/μL. ANC \>= 500/μL and \< 1,000/μL should be monitored at an increased frequency at the discretion of the investigator.
  * Hemoglobin of \>= 8.0 g/dL.
  * aPTT, PT is not to exceed 1.2 × ULN.
* Participants' chemistry values must not exceed Grade 2. Grade 2 chemistry labs should be monitored at an increased frequency at the discretion of the investigator. Participants must meet the following chemistry criteria:

  * Serum creatinine \<= 3.0 × the upper normal limit (ULN) of institution's normal range.
  * AST and ALT \<= 5.0 × the upper normal limit (ULN) of institution's normal range.
  * Bilirubin \<= 3 × ULN. Participants with Gilbert's Syndrome may be allowed to have a Bilirubin \> 3 × ULN based on a joint decision between the investigator and AbbVie medical monitor.

Exclusion Criteria:

* History of or clinically suspicious for cancer-related Central Nervous System (CNS) disease, allogeneic stem cell transplant, recurrent significant infections, previous or current malignancies within the last 5 years (except: adequately treated in situ carcinoma of the cervix uteri; basal or squamous cell carcinoma of the skin; in situ carcinoma of the bladder; previous malignancy confined and surgically resected with curative intent), toxicity from rituximab that resulted in permanent discontinuation of treatment or toxicity from ABT-263 or another Bcl-2 family protein inhibitor, significant cardiovascular disease (e.g., MI within 6 months), renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic or hepatic disease that would adversely affect participation, severe (defined as Grade 4 and/or requiring permanent discontinuation of prior antibody therapy) allergic or anaphylactic reactions to human, humanized, chimeric or murine monoclonal antibodies
* The participant has an underlying, predisposing condition of bleeding or currently exhibits signs of clinically significant bleeding. The participanthas a recent history of non-chemotherapy induced thrombocytopenic associated bleeding within six months prior to the first dose of study drug. The participant has active peptic ulcer disease or other hemorrhagic esophagitis/gastritis or active immune thrombocytopenic purpura (ITP) or a history of being refractory to platelet transfusions (within six months prior to the first dose of study drug).
* Female participant is pregnant or breast-feeding
* Participant has tested positive for HIV, Hepatitis B or Hepatitis C infection, (Participants who test positive for anti-HBc (carrier) will be allowed to enroll)
* Evidence of other clinically significant uncontrolled condition(s) including, but not limited to: active systemic fungal infection; diagnosis of fever and neutropenia within one week prior to study drug administration
* Received steroid therapy for anti-neoplastic intent within seven days prior to the first dose of study drug,received aspirin within seven days prior to the first dose of study drug, CYP3A inhibitors (e.g., ketoconazole, clarithromycin) within 7 days prior to the administration of the first dose of study drug, radio-immunotherapy within six months prior to first dose of study drug,received any anti-cancer therapy within fourteen days prior to the first dose of study drug.

Primary outcomes:
measure: Extension Study: Continued assessment of the safety profile of ABT-263 when administered in combination with rituximab
timeFrame: Safety will be assessed until the participant discontinues the extension portion of the study.
measure: Assess the safety profile and characterize the pharmacokinetics of ABT-263 when administered in combination with rituximab
timeFrame: Safety and pharmacokinetics will be assessed until the participant discontinues the study or transitions to the extension portion of the study (whichever comes first).
measure: Determination of dose limiting toxicity (DLT) and maximum tolerated dose (MTD) when ABT-263 is administered in combination with rituximab
timeFrame: DLTs and MTD will be assessed after all participants in a dose level have completed the lead-in period plus 28 days if dosing with ABT-263 and rituximab
Secondary outcomes:
measure: Extension Study: Continued assessment of the preliminary progression-free survival (PFS), response rate, and duration of response.
timeFrame: PFS will be measured upon study completion via statistical analysis of the study data.
measure: Preliminary progression-free survival (PFS), response rate, and duration of response.
timeFrame: PFS will be measured upon study completion via statistical analysis of the study data.
Other outcomes:
Locations:
city: Tucson
country: United States
facility: University of Arizona Cancer Center - North Campus /ID# 16721
state: Arizona
city: Stanford
country: United States
facility: Stanford University School of Med /ID# 9782
state: California
city: Cleveland
country: United States
facility: Cleveland Clinic Main Campus /ID# 9784
state: Ohio
city: Madison
country: United States
facility: Univ of Wisconsin Hosp/Clinics /ID# 21701
state: Wisconsin
city: Melbourne
country: Australia
facility: Peter MacCallum Cancer Ctr /ID# 25067
state: Victoria
city: Parkville
country: Australia
facility: The Royal Melbourne Hospital /ID# 9781
state: Victoria
Study officials:
affiliation: AbbVie
name: ABBVIE INC.
role: STUDY_DIRECTOR
References: